Nicholas Manusos, MBA

Mr. Nicholas (Nick) Manusos is Chief Executive Officer of Kenai Therapeutics. Previously, Mr. Manusos was founding Chief Executive Officer of Ryne Bio (Kenai’s predecessor) from company creation, seed financing and the $80+ million series A. In addition, Mr. Manusos was President and Chief Executive Officer of Opsis Therapeutics, where he led the company through a $70 million upfront funding strategic research and development alliance with Bayer-BlueRock Therapeutics. Mr. Manusos also served as founding Chief Operating Officer of Iota Biosciences resulting in a $300 million acquisition by Astellas.

Additional roles include Chief Operating Officer of FUJIFILM Cellular Dynamics Inc., where, among other accomplishments, he played a key role in the creation and eventual initial public offering of Century Therapeutics; Vice President, Global Head of Business Development at Baxter International, Inc.; Vice President, Licensing & Business Development at Takeda Pharmaceuticals; and various executive positions at Abbott Laboratories.

Mr. Manusos received his Master of Business Administration from Northwestern University, J.L. Kellogg Graduate School of Management, and his Bachelor of Business Administration in operations management from University of Wisconsin.